Sandoz, a division of Novartis, announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed adalimumab biosimilar (referencing AbbVie’s Humira).
Sandoz, a division of Novartis, announced today that the FDA has accepted its Biologics License Application (BLA) for a proposed adalimumab biosimilar (referencing AbbVie’s Humira). Sandoz reports that its comprehensive data package includes analytical as well as preclinical and clinical data, and that the submission is expected to demonstrate that the biosimilar matches the reference in terms of safety, efficacy, and quality.
"When patients are dealing with a chronic disease, it is imperative they have access to important medication that will help best manage their health," said Mark Levick, MD, PhD, global head of development, biopharmaceuticals, Sandoz, in a statement. "The FDA's acceptance of the regulatory submission for our biosimilar adalimumab brings us [1] step closer to offering a portfolio of options to the millions of patients in the [United States] who suffer from an inflammatory disease."
Clinical data in the submission include a pharmacokinetic study in healthy volunteers and a phase 3 confirmatory safety and efficacy study (ADACCES) in patients with moderate to severe chronic plaque psoriasis. In November 2017, Sandoz announced that the study met its primary endpoint in the proportion of patients who had achieved a 75% improvement in their condition at week 16 of treatment, as measured by the Psoriasis Area and Severity Index, or PASI. The study design included contiguous treatment and switched treatment arms, and the findings confirmed that there were no clinically significant differences in efficacy, safety, or immunogenicity among patients who received the biosimilar continuously, those who received the reference Humira continuously, and those who switched between the biosimilar and its reference multiple times.
Sandoz has not announced whether its study was designed to provide a basis on which the proposed therapy could be approved as an interchangeable biosimilar, but the FDA’s yet-to-be-finalized guidance on demonstrating interchangeability holds that data from switching studies be conducted in sensitive populations and include at least 3 switches.
If its biosimilar is approved, Sandoz will join Amgen (sponsor of Amgevita) and Boehringer Ingelheim (sponsor of Cyltezo) in having a challenger to the blockbuster Humira, and may also face a long wait to bring its biosimilar to market; Amgevita will not launch in the United States until 2023, and no date for Cyltezo’s launch has been announced. Meanwhile, the latest price increase to the reference Humira has been estimated by 1 analyst as having the potential to cost the US health system $1 billion in 2018 alone.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.